1 - Progress and issues for computationally guided lead discovery and optimization
Published online by Cambridge University Press: 06 July 2010
Summary
INTRODUCTION
Since the late 1980s there have been striking advances, fueled by large increases in both industrial and NIH-funded academic research, that have revolutionized drug discovery. This period has seen the introduction of high-throughput screening (HTS), combinatorial chemistry, PC farms, Linux, SciFinder, structure-based design, virtual screening by docking, free-energy methods, absorption/distribution/metabolism/excretion (ADME) software, bioinformatics, routine biomolecular structure determination, structures for ion channels, G-protein-coupled receptors (GPCRs) and ribosomes, structure/activity relationships (SAR) obtained from nuclear magnetic resonance (SAR by NMR), fragment-based design, gene knockouts, proteomics, small interfering RNA (siRNA), and human genome sequences. The result is a much-accelerated progression from identification of biomolecular target to lead compound to clinical candidate. However, a serious concern is that the dramatic increase in drug discovery abilities and expenditures has not been paralleled by an increase in FDA approvals of new molecular entities. High demands for drug safety, broader and longer clinical trials, too much HTS, too little natural products research, and effective generic drugs for many once-pressing afflictions have all been suggested as contributors. Numerous corporate mergers and acquisitions may have also had adverse effects on productivity through distractions of reorganization and integration. Nevertheless, one should consider what the success would have been in the absence of the striking technical advances. Certainly, progress with some critical and challenging target classes such as kinases would have been greatly diminished, and the adverse impact on many cancer patients would have been profound.
- Type
- Chapter
- Information
- Drug DesignStructure- and Ligand-Based Approaches, pp. 1 - 14Publisher: Cambridge University PressPrint publication year: 2010
References
High-throughput screening-driven lead discovery : Meeting the challenges of finding new therapeutics. Curr. Opin. Drug Disc. Dev. 2005, 8, 487–494.Google Scholar
The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008, 12, 306–317.Google Scholar
; ; ; ; ; ; ; From docking false-positive to active anti-HIV Agent. J. Med. Chem. 2007, 50, 5324–5329.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; GLIDE: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749.Google Scholar
; ; ; Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661–3680.Google Scholar
; ; ; ; ; ; The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222–1226.Google Scholar
; Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proc. Nat. Acad. Sci U.S.A. 2005, 102, 6665–6670.Google Scholar
; ; ; ; ; Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006, 16, 663–667.Google Scholar
; ; ; ; ; ; ; Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006, 16, 668–671.Google Scholar
; ; ; ; ; ; ; Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006, 16, 5664–5667.Google Scholar
; ; ; ; ; ; FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Am. Chem. Soc. 2006, 128, 15372–15373.Google Scholar
QIKPROP, v 3.0. New York: Schrödinger LLC; 2006.
; Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. J. Comput. Chem. 2005, 26, 1689–1700.Google Scholar
; ; ; Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004, 57, 225–242.Google Scholar
; ; Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 2006, 49, 5851–5855.Google Scholar
; ; ; Comparative performance of several flexible docking programs and scoring functions: enrichment studies for a diverse set of pharmaceutically relevant targets. J. Chem. Inf. Model. 2007, 47, 1599–1608.Google Scholar
; Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 2006, 49, 5880–5884.Google Scholar
; ; ; ; ; Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J. Chem. Info. Model. 2007, 47, 2416–2428.Google Scholar
; ; ; ; ; ; ; Extra precision GLIDE: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177–6196.Google Scholar
; ; ; ; ; ; ; ; Optimization of azoles as anti-HIV agents guided by free-energy calculations. J. Am. Chem. Soc. 2008, 130, 9492–9499.Google Scholar
; ; ; ; ; Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem. 2009, 52, 416–424.Google Scholar
; ZINC: a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177–182.Google Scholar
; ; MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 2006, 5, 399–411.Google Scholar
; ; ; ; ; Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol. Cancer Ther. 2007, 6, 1993–2002.Google Scholar
; ; ; ; ; ; ; ; ; ; Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 144–149.Google Scholar
; ; ; Crystal structure at 2.6-Å resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5191–5196.Google Scholar
; ; Prediction of drug absorption using multivariate statistics. J. Med. Chem. 2000, 43, 3867–3877.Google Scholar
; ; ; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26.Google Scholar
; Prediction of solubility from structure. Adv. Drug Deliv. Rev., 54, 355–365.
The evolution of synthetic oral drug properties. Bioorg. Med. Chem. Lett. 2005, 15, 1087–1090.Google Scholar
; ; ; ; ; ; Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550–557.Google Scholar
; In Springer Series in Chemical Physics: Free Energy Calculations: Theory and Applications in Chemistry and Biology, Vol. 86, ; ; Eds. Berlin: Springer-Verlag; 2007, 33–75.
; Monte Carlo simulation of differences in free energies of hydration. J. Chem. Phys. 1985, 83, 3050–3054.Google Scholar
; Dynamics and design of enzymes and inhibitors. J. Am. Chem. Soc. 1986, 108, 3830–3832.Google Scholar
Free energy calculations: applications to chemical and biochemical phenomena. Chem. Rev. 1993, 93, 2395–2417.Google Scholar
; Free energy perturbation simulations of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor. J. Am. Chem. Soc. 1989, 111, 5649–5658.Google Scholar
; Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J. Med. Chem. 2001, 44, 3417–3423.Google Scholar
Evaluating the molecular mechanics Poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. J. Med. Chem. 2005, 48, 7796–7807.Google Scholar
; Calculation of relative binding free energy differences for fructose 1,6-biphosphatase inhibitors using thermodynamic cycle perturbation approach. J. Am. Chem. Soc. 2001, 123, 6246–6252.Google Scholar
; ; ; ; ; ; van Structure-guided design of amp mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity. J. Am. Chem. Soc. 2007, 129, 15480–15490.Google Scholar
; Computational binding studies of orthogonal cyclosporin-cyclophilin pairs. Angew. Chem. Int. Ed. Engl. 1997, 36, 1466–1469.Google Scholar
; ; ; Monte Carlo simulations for proteins: binding affinities for trypsin-benzamidine complexes via free energy perturbations. J. Phys. Chem. 1997, 101, 9663–9669.Google Scholar
; Analysis of binding affinities for celecoxib analogs with COX-1 and COX-2 from docking and Monte Carlo simulations and insight into COX-2/COX-1 selectivity. J. Am. Chem. Soc. 2000, 122, 9455–9466.Google Scholar
; Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations. Bioorg. Med. Chem. Lett. 2001, 11, 1541–1544.Google Scholar
; ; Elucidation of fatty acid amide hydrolase inhibition by potent α-ketoheterocycle derivatives from Monte Carlo simulations. J. Am. Chem. Soc. 2005, 127, 17377–17384.Google Scholar
; ; ; Validation of a model for the complex of HIV-1 reverse transcriptase with Sustiva through computation of resistance profiles. J. Am. Chem. Soc. 2000, 122, 12898–12900.Google Scholar
; ; ; Antiviral drug design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorg. Med. Chem. Lett. 2001, 11, 2799–2802.Google Scholar
; ; Validation of a model for the complex of HIV-1 reverse transcriptase with the novel non-nucleoside inhibitor TMC125J. Am. Chem. Soc. 2003, 125, 6016–6017.Google Scholar
; ; Structural and energetic analyses for the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogs. J. Med. Chem. 2004, 46, 2389–2392.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550–2560.Google Scholar
; Perspective on free-energy perturbation calculations for chemical equilibria. J. Chem. Theor. Comput. 2008, 4, 869–876.Google Scholar
- 1
- Cited by